Abstract | PURPOSE: METHODS AND MATERIALS: RESULTS: We found no significant difference between the molgramostim and the control groups in the oral mucositis grade, oral pain, use of analgesic drugs, weight loss, or survival. The median maximum neutrophil counts (median, 9.2 x 10(9)/L vs. 5.9 x 10(9)/L, p = 0.0005), eosinophil counts (median, 1.3 x 10(9)/L vs. 0.2 x 10(9)/L, p = 0.0004), and salivary lactoferrin concentrations were higher in patients who received GM-CSF. The most common toxicities in the GM-CSF plus sucralfate group were skin reactions at the GM-CSF injection site (65%), fever (30%), bone pain (25%), and nausea (15%), whereas the toxicity of sucralfate given alone was minimal. CONCLUSION: We found no evidence indicating that subcutaneously given GM-CSF reduces the severity of radiation-induced mucositis.
|
Authors | T A Makkonen, H Minn, A Jekunen, P Vilja, J Tuominen, H Joensuu |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 46
Issue 3
Pg. 525-34
(Feb 01 2000)
ISSN: 0360-3016 [Print] United States |
PMID | 10701730
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Ulcer Agents
- Antifungal Agents
- Biomarkers
- Radiation-Protective Agents
- Sucralfate
- Granulocyte-Macrophage Colony-Stimulating Factor
- Lactoferrin
|
Topics |
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Anti-Ulcer Agents
(administration & dosage, therapeutic use)
- Antifungal Agents
(therapeutic use)
- Biomarkers
(analysis)
- Dose Fractionation, Radiation
- Female
- Granulocyte-Macrophage Colony-Stimulating Factor
(administration & dosage, therapeutic use)
- Humans
- Injections, Subcutaneous
- Lactoferrin
(analysis)
- Leukopenia
(etiology)
- Male
- Middle Aged
- Pain Measurement
- Patient Selection
- Prospective Studies
- Radiation Injuries
(blood, complications, prevention & control)
- Radiation-Protective Agents
(administration & dosage, therapeutic use)
- Saliva
(chemistry)
- Stomatitis
(blood, etiology, prevention & control)
- Sucralfate
(administration & dosage, therapeutic use)
|